Hepatitis B virus(HBV)and hepatocellular carcinoma(HCC)in sub-Saharan Africa:no room for complacency  

作　　者：Philippa C.Matthews Anna Kramvis 

机构地区：[1]The Francis Crick Institute,Midland Road,London NW14AT,UK [2]Division of Infection and Immunity,University College London,London WC1E 6BT,UK [3]Department of Infectious Diseases,University College London NHS Foundation Trust,London NW12PG,UK [4]Hepatitis Virus Diversity Research Unit,School of Clinical Medicine,Faculty of Health Sciences,University of the Witwatersrand,Johannesburg 2050,South Africa

出　　处：《Hepatoma Research》2022年第1期207-211,共5页肝癌研究（英文版）

基　　金：funding from the Wellcome Trust(Grant ref 110110/Z/15/Z);the Francis Crick Institute,London.

摘　　要：The increasing incidence and mortality of hepatocellular carcinoma(HCC)driven by hepatitis B virus(HBV)infection is a global public health concern[1].Despite World Health Organization(WHO)targets for the elimination of hepatitis as a public health problem by 2030,death attributable to viral hepatitis has continued to rise over the past decade[2],in contrast to the reduction seen in the comparable threats of human immunodeficiency virus(HIV),tuberculosis(TB)and malaria.

关 键 词：HEPATOCELLULAR MORTALITY (HBV) 

分 类 号：R73[医药卫生—肿瘤]